MIT and Microsoft researchers created an AI model to design peptide-based sensors for ultra-early cancer detection by detecting cancer-specific enzymes.
Key Details
- 1The AI model, CleaveNet, rapidly designs peptides that are efficiently and specifically cleaved by cancer-linked proteases.
- 2Nanoparticles coated with these peptides serve as in vivo sensors, releasing detectable signals in urine if target proteases are present.
- 3This approach allows non-invasive at-home cancer screening, potentially detecting and distinguishing between up to 30 cancer types.
- 4The AI-enabled sensors demonstrated high specificity for proteases such as MMP13, linked to cancer metastasis.
- 5The research appears in Nature Communications (DOI: 10.1038/s41467-025-67226-1) and is supported by ARPA-H and several foundations.
Why It Matters
AI-guided molecular sensing represents a major step towards ultra-early, highly specific cancer detection, expanding the toolkit for noninvasive diagnostics. This molecular AI approach may complement or ultimately integrate with radiology and imaging AI, enhancing multidisciplinary cancer care and research in biomarkers.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.